The adverse effects of the inhibition of microglial activation on cognitive impairment might be diminished by the targeting of microglia-expressed receptors (e.g., GLP-1R and α7nAChR agonists), although few studies on this topic have been conducted with patients with schizophrenia or animal models of the disease. This evidence concerns the gene CHRNA7 and Cognitive impairment.